Table 1.
Clinical characteristics of patients with oligodendroglial tumors that developed leptomeningeal disease compared with 196 that did not
| Total Population (n = 204) | LMD (n = 8)a | No LMD (n = 196)b | Significance (p)a vs. b | |
|---|---|---|---|---|
| Mean age in years (range) | 42 (18–78) | 40 (28–50) | 42 (18–78) | 0.636 |
| Median KPS (range) | 85 (50–100) | 85 (70–90) | 90 (50–100) | 0.477 |
| Debulking (%) | 173 (85) | 7 (87.5) | 166 (85) | 0.828 |
| Pathology at diagnosis (%) | 0.079 | |||
| • Oligo. Gr. II | 62 (30.5) | 1 (12.5) | 61 (31.1) | |
| • Oligo. Gr. III | 49 (24) | 5 (62.5) | 44 (22.4) | |
| • Mixed OA Gr. II | 52 (25.5) | 1 (12.5) | 51 (26) | |
| • Mixed OA Gr. III | 41 (20) | 1 (12.5) | 40 (20.4) | |
| 1p/19q | 0.127 | |||
| • Not tested (%) | 43 (21) | 1/7 (14) | 42 (21) | |
| • Codeletedc (% of tested) | 93/161 (58) | 6/7 (86) | 87/154 (56.4) | |
| Initial treatment (%) | 0.785 | |||
| • Observation | 96 (47) | 5 (62.5) | 91 (46) | |
| • RT alone | 35 (17) | 1 (12.5) | 34 (17.3) | |
| • ChT alone | 18 (9) | 1 (12.5) | 17 (9) | |
| • SeqRTChT | 26 (13) | 0 | 26 (13.3) | |
| • ConcRTChT | 29 (14) | 1 (12.5) | 28 (14.3) | |
| Mean number of recurrences | 1.35 | 2.88 | 1.27 | 0.001 |
| PFS (months) (mean; 95% CI) | 67 (59–75) | 47 (22–72) | 68 (59–77) | 0.176 |
| OS (months) (mean; 95% CI) | 130 (118–142) | 107 (82–132) | 133 (120–146) | 0.063 |
LMD leptomeningeal disease, Oligo oligodendroglioma, OA oligoastrocytoma, RT radiotherapy, ChT chemotherapy, SeqRTChT sequential RT followed by ChT, ConcRTChT concurrent RT and ChT, PFS progression free survival, OS overall Survival
aPatients with leptomeningeal disease
bPatients without leptomeningeal disease
cIncludes patients with only 1p loss